OM:XINT

Stock Analysis Report

Executive Summary

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Xintela's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XINT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

XINT

7.2%

SE Biotechs

4.5%

SE Market


1 Year Return

-43.0%

XINT

-30.3%

SE Biotechs

-10.2%

SE Market

Return vs Industry: XINT underperformed the Swedish Biotechs industry which returned -30.3% over the past year.

Return vs Market: XINT underperformed the Swedish Market which returned -10.2% over the past year.


Shareholder returns

XINTIndustryMarket
7 Day0%7.2%4.5%
30 Day-19.7%-16.5%-23.1%
90 Day-19.3%-14.5%-23.8%
1 Year-43.0%-43.0%-29.7%-30.3%-7.4%-10.2%
3 Year-35.0%-35.0%5.0%1.2%-0.2%-15.4%
5 Yearn/a42.1%28.7%8.5%-14.7%

Price Volatility Vs. Market

How volatile is Xintela's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Xintela undervalued compared to its fair value and its price relative to the market?

14.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate XINT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate XINT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: XINT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XINT is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XINT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XINT is overvalued based on its PB Ratio (14.2x) compared to the SE Biotechs industry average (2.9x).


Next Steps

Future Growth

How is Xintela forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Xintela has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Xintela performed over the past 5 years?

-26.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XINT is currently unprofitable.

Growing Profit Margin: XINT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XINT is unprofitable, and losses have increased over the past 5 years at a rate of -26.1% per year.

Accelerating Growth: Unable to compare XINT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (12.6%).


Return on Equity

High ROE: XINT has a negative Return on Equity (-466.91%), as it is currently unprofitable.


Next Steps

Financial Health

How is Xintela's financial position?


Financial Position Analysis

Short Term Liabilities: XINT's short term assets (SEK3.0M) do not cover its short term liabilities (SEK7.8M).

Long Term Liabilities: XINT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: XINT is debt free.

Reducing Debt: XINT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: XINT has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if XINT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XINT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: XINT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -30.8% each year


Next Steps

Dividend

What is Xintela's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate XINT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XINT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XINT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XINT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XINT's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average management tenure


CEO

Evy Lundgren-Åkerlund (62yo)

11.17s

Tenure

kr2,933,000

Compensation

Dr. Evy Lundgren-Åkerlund, BSc, Ph.D, Assoc Prof, has been the Chief Executive Officer of Xintela AB (publ) since 2009. Dr. Lundgren-Åkerlund co-founded Cartela AB in 2000 and served as its Managing Direct ...


CEO Compensation Analysis

Compensation vs Market: Evy's total compensation ($USD295.06K) is above average for companies of similar size in the Swedish market ($USD213.77K).

Compensation vs Earnings: Evy's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gregory Batcheller
Chairman of the Board & Strategic Advisor9.17yrskr118.00k1.49% SEK2.0m
Evy Lundgren-Åkerlund
Chief Executive Officer11.17yrskr2.93m10.16% SEK13.9m
Sven Kili
COO, Chief Medical Officer & Director6.17yrskr82.00k0.81% SEK1.1m
Gunnar Telhammar
CFO & Finance Director7.17yrsno datano data

8.2yrs

Average Tenure

60yo

Average Age

Experienced Management: XINT's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Gregory Batcheller
Chairman of the Board & Strategic Advisor9.17yrskr118.00k1.49% SEK2.0m
Sven Kili
COO, Chief Medical Officer & Director6.17yrskr82.00k0.81% SEK1.1m
Peter Edman
Director0.83yrno datano data
Karin Wingstrand
Director6.17yrskr59.00k0.15% SEK201.0k

6.2yrs

Average Tenure

62yo

Average Age

Experienced Board: XINT's board of directors are considered experienced (6.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24%.


Top Shareholders

Company Information

Xintela AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xintela AB (publ)
  • Ticker: XINT
  • Exchange: OM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr136.642m
  • Shares outstanding: 40.79m
  • Website: https://www.xintela.se

Number of Employees


Location

  • Xintela AB (publ)
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XINTOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKMar 2016
1XTDB (Deutsche Boerse AG)YesShare CapitalDEEURMar 2016

Biography

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. It develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. The company is developing XACT, an analytical test for cell therapy. It is also developing stem cell-based products for the treatment of osteoarthritis in humans and animals. Xintela AB (publ) has a co-development agreement with Redwood Bioscience Inc. to develop an antibody-drug conjugate therapeutic product with a focus on glioblastoma, a form of brain tumor in adults. The company was founded in 2009 and is based in Lund, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 00:51
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.